Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
6
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
national top stories
deals
new york blog main
san francisco blog main
startups
atlas venture
decibel therapeutics
dyne therapeutics
fda
gene therapy
hearing loss
investing
kaleido biosciences
myotonic dystrophy type 1
rare disease drugs
regenerative medicine
san diego blog main
adeno-associated virus
akouos
allosteric
astellas pharma
astellas pharmaceuticals
atopic dermatitis
audentes therapeutics
autoimmune disorders
avidity biosciences
azacitidine
beta-thalassemia
biotech ipos
bluebird bio
brace pharma
california institute for biomedical research
cancer
What
medicines
6
×
therapeutics
6
×
ago
developing
drug
ipo
drugs
dyne
genetic
hearing
loss
muscle
new
rare
regenerative
years
adding
address
adds
affects
aiming
aims
allosteric
americans
approach
approved
balance
based
biotech
biotechs
brings
build
called
clinic
company
considering
data
date
debuts
decibel
Language
unset
Current search:
medicines
×
therapeutics
×
boston
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
